TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12063831
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 5‐FU and radiation
Study: 9627274
Drug: Enalaprilat (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalaprilat (0.5 mg bolus followed by incremental infusion up to 10 mg, mean 8.3 mg)
Study: 2231061
Drug: Screening for
Normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening for oral cancer; no specific intervention details provided.
Study: 362197
Drug: 10‐mg clotrimazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐mg clotrimazole buccal troches taken five times daily for two weeks
Study: 362197
Drug: Placebo taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken five times daily for two weeks
Study: 30958973
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (0.1 g·kg‐1·day‐1 of creatine + 0.1 g·kg‐1·day‐1 of maltodextrin) during 8 weeks of HVRT
Study: 30958973
Drug: Placebo (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.2 g·kg‐1·day‐1 of maltodextrin) during 8 weeks of HVRT
Study: 23334268
Drug: Local administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local administration of piperacillin/tazobactam
Study: 10768702
Drug: Methadone hydrochloride
Normalized name: Methadone Hydrochloride
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methadone hydrochloride dose increase to 70 mg/d (n = 31 patients)
Study: 10768702
Drug: Combined contingent
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined contingent vouchers and methadone dose increase (n = 32 patients)
Study: 8808718
Drug: Lomefloxacin 400
Normalized name: lomefloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomefloxacin 400 mg once daily for 15 days
Study: 8808718
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg twice daily for 15 days
Study: 1425877
Drug: nalbuphine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: nalbuphine (0.2 mg.kg‐1 i.v.)
Study: 4016785
Drug: Low-dose treatment
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose treatment strategy (2 X 10(6) units/m2 daily for 28 days, then daily for 5 days every other week by im injection)
Study: 4016785
Drug: High-dose treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose treatment strategy (5 X 10(6) units/m2 by continuous iv infusion over 24 hours, escalating by 5 X 10(6) units/m2/day as tolerated over 10 days, repeated every 28 days)
Study: 27796466
Drug: Netazepide 1
Normalized name: Netazepide
DrugBank: Netazepide (DB12355)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netazepide 1 mg
Study: 27796466
Drug: Netazepide 5
Normalized name: Netazepide
DrugBank: Netazepide (DB12355)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netazepide 5 mg
Study: 27796466
Drug: Netazepide 25
Normalized name: Netazepide
DrugBank: Netazepide (DB12355)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netazepide 25 mg
Study: 27796466
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg daily for 28 days
Study: 23446906
Drug: High-protein (HP)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein (HP) breakfast (350-kcal, 35 g protein)
Study: 23446906
Drug: Normal-protein (NP)
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-protein (NP) breakfast (350-kcal, 13 g protein)
Study: 19326695
Drug: SPF 40
Normalized name: Solbar Shield Suncreen SPF 40
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SPF 40 sunscreen cream containing ecamsule 3%, octocrylene 10%, avobenzone 2%, and titanium dioxide 5% (tetrad)
Study: 19326695
Drug: Ecamsule-deprived cream
Normalized name: ecamsule
DrugBank: Ecamsule (DB09534)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ecamsule-deprived cream (triad-E)
Study: 19326695
Drug: Avobenzone-deprived cream
Normalized name: Avobenzone
DrugBank: Avobenzone (DB09495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Avobenzone-deprived cream (triad-A)
Study: 16957433
Drug: Topical retapamulin
Normalized name: retapamulin Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical retapamulin ointment, 1% for 5 days twice daily
Study: 16957433
Drug: Oral cephalexin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cephalexin, 500 mg twice daily for 10 days
Study: 11703421
Drug: Metformin (MG)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (MG)
Study: 7536071
Drug: Low-dose cyclophosphamide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclophosphamide (LD-CY, 1500 mg/m2) plus cisplatin (CDDP) 100 mg/m2 (OvCa) or epirubicin (EPR) 120 mg/m2 (BrCa) plus recombinant human G-CSF (rhG-CSF)
Study: 7536071
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HDC) with carboplatin 1200 mg/m2, etoposide 900 mg/m2 and melphalan 100 mg/m2 with reinfusion of PBSC
Study: 3148298
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of human milk since the 15th day of TPN
Study: 3148298
Drug: Oral metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral metronidazole since the 15th day
Study: 3148298
Drug: Parenteral antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral antibiotic therapy for septicemia since the 1st day
Study: 28736267
Drug: Gamma tocopherol
Normalized name: Gamma tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma tocopherol (γT) 1200 mg daily for 14 days
Study: 21518073
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (n=85) received an educational session, dental supplies, and scheduled oral care appointment.
Study: 8366188
Drug: famotidine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine 2.5 mg
Study: 8366188
Drug: famotidine 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine 5.0 mg
Study: 8366188
Drug: famotidine 10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine 10.0 mg
Study: 8366188
Drug: famotidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine 0.5 mg
Study: 30276974
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with paclitaxel and cisplatin
Study: 27483185
Drug: Monthly text
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly text message checking contact details (Control)
Study: 15829782
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A injection into the mid-belly of the muscle bulks (distal group)
Study: 15829782
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A injection into the proximal part of both heads of the gastrocnemius (proximal group)
Study: 12810404
Drug: MLCT diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLCT diet (14 g of MLCT containing 1.7 g MCFA daily at breakfast for 12 weeks)
Study: 9795914
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg lamivudine once daily
Study: 9795914
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg lamivudine once daily
Study: 83330
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rapid smoking and covert sensitization
Study: 24172309
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g MCT oil/d
Study: 24172309
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g corn oil/d
Study: 19014838
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of clarithromycin extended-release 500-mg tablets under fasting conditions
Study: 19014838
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of clarithromycin extended-release 500-mg tablets under fasting conditions
Study: 19014838
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of clarithromycin extended-release 500-mg tablets under fed conditions
Study: 19014838
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of clarithromycin extended-release 500-mg tablets under fed conditions
Study: 16047460
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg twice daily
Study: 9381885
Drug: Vaginal suppositories
Normalized name: Miconazole Nitrate Vaginal Suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal suppositories of 'Zhlemik'
Study: 2210463
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg four times daily)
Study: 31751759
Drug: Oral immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunotherapy (OIT) for hazelnut allergy for at least 6 months.
Study: 31751759
Drug: Baseline eliciting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline eliciting dose of hazelnut protein was 106 mg (IQR, 51-249); after 6 months of OIT, it increased to 523 mg (IQR, 190-1635) (P < .0001).
Study: 30341774
Drug: Topical regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical regorafenib (25 μl, 30 mg ml‐1) three times a day for 12 weeks
Study: 30341774
Drug: Ocular treatment‐emergent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocular treatment‐emergent adverse events (TEAEs)
Study: 30341774
Drug: Rescue treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue treatment (intravitreal ranibizumab)
Study: 25802037
Drug: Aerobic interval
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic interval training (AIT) for 12 weeks (three weekly sessions lasting 38 min with ≈ 16 min at 85‐90% of VO2peak)
Study: 21383284
Drug: Fluorouracil and
Normalized name: Fluorouracil and salicylic acid only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil and folinic acid chemotherapy
Study: 17255220
Drug: Dihydroartemisinin suppository
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin suppository (DHA)
Study: 17255220
Drug: Intramuscular artemether
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular artemether (ART)
Study: 15472673
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of aqueous sodium phosphate (45 mL each)
Study: 15472673
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of aqueous sodium phosphate
Study: 15472673
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of aqueous sodium phosphate
Study: 26485846
Drug: Combined topical
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined topical anal lignocaine ointment and local infiltration anesthesia (G2)
Study: 17139644
Drug: Arthroscopic lavage
Normalized name: lovage oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthroscopic lavage plus administration of corticosteroids (ALC)
Study: 17139644
Drug: Joint aspiration
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Joint aspiration plus administration of corticosteroids (JAC)
Study: 17139644
Drug: Arthroscopic lavage
Normalized name: lovage oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthroscopic lavage plus administration of placebo (ALP)
Study: 10750366
Drug: Argatroban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argatroban (10 mg intravenous drip infusion)
Study: 1630802
Drug: Anti-HCV antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-HCV antibody positive patients in chronic haemodialysis
Study: 17644412
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of KW-3902 (selective A1 adenosine receptor antagonist)
Study: 16326292
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion plus 10 microg/kg of intrathecal morphine (ITM group, n = 23)
Study: 16326292
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion alone (control group, n = 23)
Study: 9817281
Drug: Standard-dose m-BACOD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose m-BACOD plus GM-CSF
Study: 819200
Drug: Treatment in
Normalized name: Other agents for local oral treatment in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment in air with a modal tumour dose of 6000 rad in 24 fractions over approximately 5 weeks.
Study: 819200
Drug: Treatment in
Normalized name: Other agents for local oral treatment in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment in hyperbaric oxygen (3 atm) with a modal tumour dose of 6000 rad in 24 fractions over approximately 5 weeks.
Study: 819200
Drug: Cumulative Radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cumulative Radiation Effect (CRE) analysis of treatment regimes.
Study: 22863021
Drug: Rapid Syllable
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid Syllable Transition Treatment
Study: 19602554
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone + Testosterone (GH+T)
Study: 15117375
Drug: Benzoyl peroxide/clindamycin
Normalized name: BENZOYL PEROXIDE/CLINDAMYCIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzoyl peroxide/clindamycin topical gel (5% benzoyl peroxide and 1% clindamycin)
Study: 15117375
Drug: Benzoyl peroxide/clindamycin
Normalized name: BENZOYL PEROXIDE/CLINDAMYCIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzoyl peroxide/clindamycin topical gel
Study: 12478408
Drug: Oral valacyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral valacyclovir (2 g q.i.d.)
Study: 8012963
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) at 3.9 mg/kg and Ciprofloxacin (Cipro) 500 mg p.o. every 12 h on days 1-5 and 10-20.
Study: 2595345
Drug: Tenoxicam 20
Normalized name: tenoxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 20 mg daily
Study: 28028737
Drug: 1-month sustained-release
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-month sustained-release triptorelin
Study: 28028737
Drug: 3-month sustained-release
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-month sustained-release triptorelin
Study: 28028737
Drug: 6-month sustained-release
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month sustained-release triptorelin
Study: 28028737
Drug: 9-month sustained-release
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-month sustained-release triptorelin
Study: 28028737
Drug: 12-month sustained-release
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month sustained-release triptorelin
Study: 23370795
Drug: 0.1 mg/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/70 kg i.v. buprenorphine in humans
Study: 23370795
Drug: 0.04 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.04 mg/kg i.v. buprenorphine in rats
Study: 23370795
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg i.v. buprenorphine in rats
Study: 8957980
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 1000 ml (Group C)
Study: 8957980
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 500 ml (Group B)
Study: 31172873
Drug: Chewing gum
Normalized name: Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewing gum containing 7.5 mg of sodium metaphosphate (SMP)
Study: 26681715
Drug: LY2409021 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2409021 20 mg
Study: 26659938
Drug: Restylane‐L
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restylane‐L
Study: 22311679
Drug: Outpatient chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient chemotherapy with S-1 + cisplatin (S-1: 80-120 mg days 1-21; cisplatin: 60 mg/m2 day 8, every 4-5 weeks)
Study: 22311679
Drug: Inpatient chemotherapy
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient chemotherapy with intravenous hydration (control group)
Study: 8947984
Drug: Restrictive formulary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive formulary (dosage strengths of 25, 50, 100, 125, and 150 micrograms)
Study: 8947984
Drug: Nonrestrictive formulary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonrestrictive formulary (dosage strengths of 25, 50, 75, 100, 112, 125, 150, 175, 200, and 300 micrograms)
Study: 7104460
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 40 mg oral propranolol hydrochloride tablets
Study: 7104460
Drug: Innovator's product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Innovator's product (reference tablet)
Study: 30916379
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg every week (ADAew)
Study: 27301417
Drug: Indacaterol/glycopyrronium (IND/GLY)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol/glycopyrronium (IND/GLY) 110/50 μg once daily (OD)
Study: 24526247
Drug: Acetaminophen/tramadol 325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen/tramadol 325 mg/37.5 mg per capsule, maximum acetaminophen 1,950 mg and tramadol 225 mg per day; treatment duration 2 weeks.
Study: 24526247
Drug: Placebo, titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, titrated identically to treatment.
Study: 19460715
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy combined with trastuzumab
Study: 15867582
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (0.05 mg/kg per day)
Study: 12062539
Drug: High-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose aspirin (1000 mg bolus given 1 day before angioplasty)
Study: 12062539
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (100 mg/day only)
Study: 12062539
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no aspirin intervention)
Study: 9828247
Drug: High-dose epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose epinephrine (5 mg each, up to 15 doses)
Study: 9828247
Drug: Standard-dose epinephrine
Normalized name: epinephrine Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose epinephrine (1 mg each, up to 15 doses)
Study: 10220206
Drug: Soluble insulin
Normalized name: Soluble insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Soluble insulin + NPH (20‐30 min before each meal and NPH at bedtime)
Study: 1703916
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy followed by definitive radiation therapy (RT) - 70 Gy to involved areas and 50 Gy to uninvolved neck at 2 Gy/fraction, five fractions per week.
Study: 1703916
Drug: Alternating chemotherapy
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating chemotherapy and radiation therapy (RT) - 60 Gy to involved areas and 50 Gy to uninvolved neck in three courses of 20 Gy each, 2 Gy/fraction, ten fractions/2 weeks alternated with four courses of chemotherapy.
Study: 29304531
Drug: Dietary nitrate
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary nitrate supplement (SiS nitrate gel)
Study: 23290154
Drug: Theophylline plus
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline plus SFC (200 mg theophylline plus 50/250 μg SFC)
Study: 23290154
Drug: SFC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFC plus placebo (placebo tablet plus 50/250 μg SFC)
Study: 31605923
Drug: Budesonide/glycopyrrolate/formoterol fumarate
Normalized name: budesonide/glycopyrrolate/formoterol fumarate 160 mcg-9 mcg-4.8 mcg/actuation INHALATION HFA AEROSOL WITH ADAPTER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) 320/18/9.6 μg
Study: 31605923
Drug: Budesonide/glycopyrrolate/formoterol fumarate
Normalized name: budesonide/glycopyrrolate/formoterol fumarate 160 mcg-9 mcg-4.8 mcg/actuation INHALATION HFA AEROSOL WITH ADAPTER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) 160/18/9.6 μg
Study: 31605923
Drug: Glycopyrrolate/formoterol fumarate
Normalized name: glycopyrrolate/formoterol fumarate 9/4.8 MCG/INHAL Metered Dose Inhaler, 120 Actuations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate/formoterol fumarate (GFF) MDI 18/9.6 μg
Study: 31605923
Drug: Budesonide/formoterol fumarate
Normalized name: budesonide/formoterol fumarate 80/4.5 MCG/INHAL Metered Dose Inhaler, 60 Actuations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol fumarate (BFF) MDI 320/9.6 μg